Trial Profile
An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Nov 2023
Price :
$35
*
At a glance
- Drugs Cediranib (Primary) ; Durvalumab (Primary) ; Olaparib (Primary) ; Tremelimumab (Primary) ; Doxorubicin liposomal; Paclitaxel; Topotecan
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Biomarker; Therapeutic Use
- Acronyms AMBITION
- 09 Nov 2023 Results of sub-study comparing the efficacy and safety of two olaparib-based combinations and biomarkers of patients with platinum-resistant ovarian cancer with HRR gene mutations ,published in the International Journal of Cancer.
- 08 Jun 2021 Results (n=70) presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 29 Mar 2021 Planned number of patients changed from 86 to 104.